Literature DB >> 8158202

Clinical implementation of anti-acetylcholine receptor antibodies.

K Toyka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8158202      PMCID： PMC1072846          DOI： 10.1136/jnnp.57.3.396

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  4 in total

1.  Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis.

Authors:  F M Howard; V A Lennon; J Finley; J Matsumoto; L R Elveback
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

2.  Effect of myasthenic IgG on degradation of junctional acetylcholine receptor.

Authors:  G Takeo; M Motomura; H Mats; K Ohishi; T Yoshimura; M Tsujihata; S Nagataki
Journal:  Muscle Nerve       Date:  1993-08       Impact factor: 3.217

3.  Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity.

Authors:  U A Besinger; K V Toyka; M Hömberg; K Heininger; R Hohlfeld; A Fateh-Moghadam
Journal:  Neurology       Date:  1983-10       Impact factor: 9.910

4.  The human-severe combined immunodeficiency myasthenic mouse model: a new approach for the study of myasthenia gravis.

Authors:  G Martino; B L DuPont; R L Wollmann; P Bongioanni; J Anastasi; J Quintans; B G Arnason; L M Grimaldi
Journal:  Ann Neurol       Date:  1993-07       Impact factor: 10.422
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.